Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

AN2 Therapeutics Inc
Healthcare
P/NCAV
0.58x
Ticker
ANTX
Exchange
NASDAQ
Country
United States
Close
2.37 $
Mkt Cap
55.9M $
EV
40.3M $
NCAV Burn Rate
-5.5%
Current Ratio
7.87
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.6x
EV/FCF
-0.8x
Dilution
5.9% p.A
Total Net Income
-146.5M $
Cheapness
100.0%
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average